This is a free preview of a paid episode. To hear more, visit
www.mendelspod.comToday, we pursue an exciting area of medicine for the first time: cell therapy for solid tumors.Most, if not all, of our audience will be familiar with the success of CAR-T therapies for blood cancers. But only 10% of cancer is in the blood. The other 90% develop solid tumors. Jason Bock is the CEO and founder of CTMC, a new company aiming to speed the advancement of the entire field of cell therapies. First, we cover this new treatment for solid tumors and discuss the near-science-fiction action of tumor-infiltrating lymphocytes (til).
Mendelspod Podcast